Mentavi has already done the hardest thing in digital mental health — a clinically validated, psychologist-reviewed diagnostic platform with a national clinical network and peer-reviewed evidence in The Journal of Clinical Psychiatry. The next chapter is making sure the adults who need it, and the operators who can scale it, actually find Mentavi first.
You already organized the evidence the rest of the category can't. The remaining job is making sure the people who need that evidence end up in front of it on the day they start looking.
Mentavi is the rare operator in this category. ADHD Online in 2018, Mentavi Health by 2024, JCP-validated by 2025 with 80.6% sensitivity and 94.9% positive predictive value on the adult ADHD diagnostic — numbers no other telehealth diagnostic instrument carries at this scope. A national clinical network: licensed therapists in 42 states, prescribing professionals in 41, mental wellness coaches in all 50. Two products that fit together — the Diagnostic Evaluation at $199 and the Mental Wellness Snapshot at $29.99. The clinical machine is real.
What the demand side does not yet match is the clinical side. There are 17 million American adults with ADHD alone, and that's before anxiety, depression, OCD, sleep, and the twenty-three other conditions Mentavi screens for. Most of them are sitting on a six-month specialist waitlist or starting a course of treatment without a clear diagnostic picture. They will be searching this week. The question is whether Mentavi is the first answer they trust.
This proposal is about the second engine — the demand infrastructure that sits next to the clinical one and feeds both motions. The D2C funnel where the newly-curious adult finds the $199 eval at 11pm, and the B2B/B2B2C funnel where a counseling center director, a multi-state psychiatric group, or a benefits leader discovers that done-for-you and white-label diagnostic workflows can recapture clinician time and unlock new CPT-billable revenue. Built so that whichever direction a buyer enters, Mentavi is the first credible answer.
One last frame. Mentavi has two growth motions running parallel, and the right unit of growth is different for each. D2C governs to cost-per-completed-diagnostic-evaluation — the moment Mentavi has both clinical evidence and revenue. B2B governs to cost-per-qualified-pipeline-discovery-call with a real operator. Snapshot enterprise governs to cost-per-employer-pilot-contract. Three honest numbers, three engines, one company. Every section below is engineered against that map.
Directional twelve-month targets, set against AYMI's published healthcare work (Oscar Health, Florida Blue) and B2B enterprise pipeline. Honestly held, not promised — the contract on numbers is for the scoping call.
All figures directional. Anchored to AYMI's published healthcare and B2B enterprise case studies (see §XIII) and to category-published telehealth and digital mental-health benchmarks. The actual contract on numbers belongs to the scoping call — once the D2C/B2B budget split, the LTV graduation curve, and the clinical-capacity ceiling are real.
Persona-led, not motion-led. Each enters Mentavi with a different question. The funnel earns the right to answer it.
If we do one thing first, it is this. Everything else compounds off it.
The clinical engine already exists at Mentavi. The validation exists. The clinical network exists. The product ladder exists. What does not yet exist as engineered systems are the two demand engines that feed it — D2C and B2B/B2B2C running in parallel, each governed against its own honest unit, each compounding into the LTV the platform already deserves.
The promise we are not making: an avalanche of $199 evals in week three or a fortune-50 logo in month two. The promise we are making: a measured, defensible engine on both sides of Mentavi's funnel that gets cheaper every quarter, governed honestly against clinical-network capacity, audited monthly, and ownable by Mentavi at any point.
Mentavi already owns the rarest asset in this category — an adult ADHD diagnostic validated in The Journal of Clinical Psychiatry with named co-authors, 80.6% sensitivity, and 94.9% positive predictive value. That paper exists. So does the Psych Congress Elevate 2026 poster, the Mental Wellness Snapshot launch, and the Tech Week GR keynote on credible innovation. What's missing is the surface that turns this evidence pile into the answer to the queries adults and operators are searching today.
The adult who fills out Mentavi's evaluation tonight searched for something specific this week. Sometimes it was the name of the condition; sometimes it was the inability to focus at a 2pm meeting; sometimes it was their partner's suggestion. The paid engine needs to meet all three. Creative is identity-neutral, claim-free, and built per the AYMI healthcare-vertical house rules — no patient faces, no demographic cues, no on-frame outcome stats. The validation language belongs on the lander, not on the ad.
PURCHASE on the completed $199 eval, with the started-eval and qualified-quiz events as supporting signals for audience and lookalike buildingThe B2B side is where Mentavi has the most room to compound and where Corey's own LinkedIn presence is already the leading edge. Health-system directors, multi-state telehealth COOs, university counseling-center leaders, structured psych-practice operators — this is a small, named, knowable buyer set. Mentavi doesn't need a million-impression campaign here; it needs a measured engine that reaches the right two thousand operators credibly and frequently.
Three intakes, each with its own conversion mechanics. The D2C eval intake is a paid-up-front transaction with a five-day clinical SLA — trust is the entire job. The B2B intake is a discovery call — calendar fit and the perceived prep gap are the levers. The Snapshot pilot intake is a procurement step — legal, security, and outcomes-data clarity are the levers. The platform's CRO program should treat them as three different funnels, because they are.
The invisible loss in adult-diagnostic care is between the completed eval and the next clinical step — the patient who got results, didn't book a follow-up, and went quiet. The lifecycle surface respects that without manufacturing urgency. Same on the B2B side: an operator who took a discovery call but went silent is rarely a "no" — they are a quarterly budget cycle away. Lifecycle keeps Mentavi in the room without intruding.
When the answer to "who runs the ads?" is already named, already specialized, and already in the house — the proposal stops being theoretical.
This section exists because Mentavi is the rare prospect where the question is moot. ADKlinic is AYMI's healthcare-only performance practice — built as a dedicated arm, not a generalist agency leaning into healthcare for the season. Twenty-two specialty playbooks, BAA-ready infrastructure, a compliance posture that starts at server-side tracking and ends at the SQL row connecting a click to an authorized appointment. Behavioral Health & Psychiatry is one of those twenty-two specialties. Mentavi is the most evidence-backed national operator in it. The fit isn't a pitch. It's the reason this section is here.
"Your ad agency has never heard of a CPT code." That ad tested high enough to bring you here because it named a structural fact about the category. ADKlinic exists because generic agencies don't index by specialty, don't model PAC against CPT-billable revenue, and don't write a compliance posture into the campaign architecture. They learn behavioral health on the client's dollar. ADKlinic learned it before the engagement.
The stack runs in six disciplines, each tuned to Mentavi's actual funnel:
ADKlinic's signature first move is the audit — PAC benchmarked against the behavioral-health specialty band, competitor analysis modeled across BetterHelp, Cerebral, Talkspace, and the regional players, server-side tracking implemented, BAA signed, compliant attribution running before the first new dollar moves. The picture exists before the engine turns on. That is the first thirty days of any Mentavi engagement, full stop.
The two usual options in this category are a generalist learning the regulatory environment on your dollar, or a smaller shop that knows healthcare but can't ship at scale. The third option is the one already in this proposal.
A JCP-published validation is the rarest asset in this category. Make it the brand, not just a press release archive.
Mentavi's adult ADHD diagnostic was independently studied and published in The Journal of Clinical Psychiatry — 80.6% sensitivity, 94.9% positive predictive value. No other telehealth diagnostic instrument carries a peer-reviewed validation at this scope. Most adult-mental-health competitors in the category compete on accessibility or price. Mentavi has rigor.
The recommendation is to thread the validation story through every surface — not as a clinical claim but as a translated promise:
The surfaces where this lives: the hero on every D2C lander, the first email of every nurture, a single visual treatment in the creative bank that reappears across paid social, the clinician-byline pieces, the AI-answer schema for the "is this legitimate" query family, the credibility section of every B2B deck, the broker-targeted Snapshot one-pager. All consistent. All evidence-fluent. None of them implying outcomes the JCP paper does not.
Mentavi's quietest superpower is that the rigor extends past the headline. The clinical co-authors are publicly verifiable, the methodology is replicable, the sensitivity/PPV numbers are stable across the published cohort. That makes the validation defendable in every room where someone tries to dismiss "online mental health" as a category. Make defendability legible.
If we build it, we govern it. The dashboard is how we keep both motions honest.
Included with the Growth System and Full Demand OS engagement shapes: a custom AYMI dashboard that pulls from your Meta and Google ad accounts, your D2C analytics surface, your B2B CRM, and (with Mentavi's permission and a BAA where appropriate) the completed-evaluation and graduation data that makes "cost-per-completed-eval" and "graduation rate" real metrics, not vibes. Refreshed daily. Available to Corey, the marketing team, and the leadership group. Reviewed in a monthly call. No agency black-box.
What it shows, in plain views:
The point of the dashboard is not the chrome. It is the visible truth of both engines, in one place, every day. If a $199 eval is acquired at a CAC that the LTV graduation curve can't justify, the dashboard says so before the month closes — not at the QBR three weeks later.
Rather than a price ladder pasted into a proposal, three engagement shapes scoped to where Mentavi is today.
Mentavi is in a window most adult-mental-health platforms never get to occupy — the clinical machine is real, the JCP validation is published, the rebrand is settling into a coherent brand house, and Corey is already the leading edge of a B2B motion that has the legs to compound. The 17-million-adult ADHD market alone is a single condition out of the 29 the platform screens for. The PE-backed competitors in adjacent space have scale, but they don't have Mentavi's evidence base.
Foundation underbuilds the moment — it can ship the system, but not the active dual-motion velocity Mentavi's window calls for. Full Demand OS is the right shape for a national-authority operator, not yet the right twelve-month commitment given that the LTV graduation curve and the Snapshot enterprise motion are still being characterized. The Growth System is the right shape for the next twelve months: enough engine to compound on both motions, not so much that it outruns the clinical-network capacity or the management team's bandwidth to govern it.
The first ninety days of any engagement are scoped tightly below.
Three healthcare engagements built on the same discipline Mentavi already lives in: compliance-aware, qualified-outcome-driven, measured to the conversion that matters — not the click.
Why this maps: turning a regulated, compliance-tight enrollment window into an intent-tiered acquisition system measured to approved members, not clicks. The same qualified-outcome discipline Mentavi's $199 completed evaluation requires — and the same back-solve from LTV that the eval→treatment graduation curve will run on.
Why this maps: a compliance-first regional payer growth system built market-by-market. The closest AYMI analog to Mentavi's national-but-state-by-state behavioral health roll-out — run with the same regulatory care Mentavi already brings to clinical workflow, and a retention curve that mirrors the LTV math Mentavi's lifecycle layer is engineered to compound.
Why this maps: a high-trust, low-volume B2B motion where every qualified conversation matters. The same compounding ABM mechanics Mentavi's named-account list will run on — health systems, multi-state telehealth groups, structured psychiatric practices, university counseling centers.
If Mentavi builds the second engine now, the first one stops being the rate limiter.
There are 17 million American adults with ADHD alone. Most of them are sitting on a six-month specialist waitlist, or trial-and-erroring their way through care without a clear diagnostic picture, or telling themselves it's just stress. Mentavi already has the answer they need — clinically validated, psychologist-reviewed, peer-reviewed in The Journal of Clinical Psychiatry. What's missing is the engine that puts the answer in front of them on the day they start looking.
And on the B2B side, there are roughly five hundred named operators in the United States who could be running Mentavi's white-label diagnostic infrastructure tomorrow. They don't yet know the category exists. The demand engine for them is just as buildable, just as measurable, and just as governable.
That's what this proposal is for.
We'd close on Growth System scope, lock the first thirty-day sprint, and put the kick-off date on the calendar. We can also walk through the companion creative preview on the call — six concept frames in both D2C and B2B registers, built to AYMI's healthcare house rules.